top of page

Behavioral Health & Nervous System

Neurotransmitter Synthesis, Storage, Release, Degradation; Major Receptor Classes; Pharmacologic Modulation

Core Principle of Neurotransmitter Pharmacology
🧷 Every neurotransmitter has a lifecycle: synthesis, vesicular storage, release, receptor binding, and termination of action (reuptake, enzymatic degradation, or diffusion).
🧷 Each step is a potential pharmacologic target. Drugs that modify neurotransmitter systems work by enhancing or inhibiting one or more of these steps.
🧷 Board questions test the synthesis pathways, rate-limiting enzymes, receptor subtypes, degradation routes, and how specific drugs alter signaling at each point.
Solid White Background
Acetylcholine: Synthesis and Degradation
📍 Synthesis: choline + acetyl-CoA → ACh, catalyzed by choline acetyltransferase (ChAT) in the presynaptic terminal.
📍 Storage: ACh is packaged into vesicles by the vesicular acetylcholine transporter (VAChT).
📍 Release: Ca²⁺-dependent exocytosis via SNARE proteins.
📍 Degradation: acetylcholinesterase (AChE) in the synaptic cleft rapidly hydrolyzes ACh into choline and acetate. Choline is recycled via a high-affinity choline transporter back into the presynaptic terminal.
📍 Board pearl: AChE inhibitors (neostigmine, pyridostigmine, donepezil) increase ACh in the cleft. Hemicholinium blocks choline reuptake. Vesamicol blocks vesicular storage. Botulinum toxin blocks release.
Solid White Background
Acetylcholine: Receptor Classes
🔹 Nicotinic receptors (ionotropic, ligand-gated Na⁺ channels): NM subtype at the NMJ (skeletal muscle), NN subtype at autonomic ganglia (both sympathetic and parasympathetic) and in the CNS.
🔹 Muscarinic receptors (metabotropic, G-protein coupled): M1 (Gq, CNS and gastric parietal cells), M2 (Gi, heart — decreases rate), M3 (Gq, smooth muscle contraction, glandular secretion).
🔹 Board pearl: Nicotinic = fast, ionotropic, NMJ and ganglia. Muscarinic = slow, metabotropic, end-organ parasympathetic effects. Atropine blocks muscarinic receptors. Succinylcholine activates nicotinic NM receptors.
Solid White Background
Catecholamines: Synthesis Pathway
⭐ Tyrosine → L-DOPA (by tyrosine hydroxylase, the rate-limiting enzyme) → dopamine (by DOPA decarboxylase, requires vitamin B6/pyridoxine) → norepinephrine (by dopamine beta-hydroxylase, requires vitamin C) → epinephrine (by phenylethanolamine N-methyltransferase, PNMT, in the adrenal medulla).
⭐ Storage: vesicular monoamine transporter (VMAT) packages catecholamines into vesicles. Reserpine blocks VMAT, depleting monoamine stores.
⭐ Board pearl: Tyrosine hydroxylase is the rate-limiting step for all catecholamines. The pathway branches at dopamine — dopaminergic neurons lack dopamine beta-hydroxylase and cannot make NE.
Solid White Background
Dopamine: Pathways and Receptors
✅ Four major pathways: nigrostriatal (movement), mesolimbic (reward, positive psychotic symptoms), mesocortical (cognition, negative symptoms), tuberoinfundibular (prolactin inhibition).
✅ Degradation: MAO-B and COMT → homovanillic acid (HVA).
✅ D1 family (D1, D5): Gs-coupled, excitatory. D2 family (D2, D3, D4): Gi-coupled, inhibitory.
✅ Board pearl: D2 blockade in the mesolimbic pathway = antipsychotic effect. D2 blockade in the nigrostriatal pathway = EPS/parkinsonism. D2 blockade in the tuberoinfundibular pathway = hyperprolactinemia.
Solid White Background
Norepinephrine: Synthesis, Receptors, and Degradation
🧠 Synthesized from dopamine by dopamine beta-hydroxylase. Primary CNS source: locus coeruleus (arousal, attention, anxiety).
🧠 Receptors: alpha-1 (Gq, vasoconstriction, mydriasis), alpha-2 (Gi, presynaptic autoreceptor inhibiting NE release, central sympatholytic), beta-1 (Gs, cardiac stimulation, renin release), beta-2 (Gs, bronchodilation, vasodilation).
🧠 Degradation: MAO and COMT → vanillylmandelic acid (VMA) and metanephrines (urinary markers for pheochromocytoma).
🧠 Reuptake: norepinephrine transporter (NET). Cocaine and TCAs block NET.
🧠 Board pearl: Urinary VMA and metanephrines are the screening tests for pheochromocytoma. Clonidine (alpha-2 agonist) reduces central sympathetic outflow.
Solid White Background
Serotonin: Synthesis, Receptors, and Degradation
⚡ Synthesis: tryptophan → 5-hydroxytryptophan (by tryptophan hydroxylase, rate-limiting) → serotonin/5-HT (by aromatic amino acid decarboxylase, requires B6).
⚡ CNS source: dorsal raphe nuclei (mood, anxiety, sleep, appetite, pain modulation).
⚡ Key receptors: 5-HT1A (Gi, anxiolytic target of buspirone), 5-HT2A (Gq, hallucinogenic target, blocked by atypical antipsychotics), 5-HT3 (ionotropic, vomiting center — ondansetron blocks), 5-HT4 (Gs, GI prokinetic).
⚡ Degradation: MAO-A → 5-HIAA (elevated in carcinoid syndrome).
⚡ Reuptake: serotonin transporter (SERT). SSRIs block SERT.
⚡ Board pearl: Elevated urinary 5-HIAA = carcinoid tumor. Serotonin syndrome = excess serotonergic activity (clonus, hyperthermia, agitation).
Solid White Background
GABA: Synthesis, Receptors, and Pharmacology
📌 Synthesis: glutamate → GABA by glutamic acid decarboxylase (GAD), which requires pyridoxine (vitamin B6) as a cofactor.
📌 GABA-A (ionotropic, Cl⁻ channel): benzodiazepines increase FREQUENCY of channel opening; barbiturates increase DURATION. Ethanol also enhances GABA-A.
📌 GABA-B (metabotropic, Gi): baclofen is the agonist (used for spasticity). Opens K⁺ channels and closes Ca²⁺ channels.
📌 Board pearl: Isoniazid depletes pyridoxine → decreased GAD activity → decreased GABA → seizures. Treat INH-induced seizures with pyridoxine (B6).
Solid White Background
Glutamate: The Primary Excitatory Neurotransmitter
📣 Glutamate is the major excitatory neurotransmitter in the CNS.
📣 AMPA receptors (ionotropic): mediate fast excitatory transmission (Na⁺ influx).
📣 NMDA receptors (ionotropic): require both glutamate and depolarization (to relieve Mg²⁺ block). Permeable to Ca²⁺. Critical for LTP and memory. Excitotoxicity from excessive NMDA activation (Ca²⁺ overload) contributes to neuronal death in stroke and neurodegeneration.
📣 Metabotropic glutamate receptors (mGluRs): modulatory roles.
📣 Board pearl: Memantine (NMDA antagonist) is used in moderate-to-severe Alzheimer disease. Ketamine and PCP are also NMDA antagonists (produce dissociative anesthesia/psychosis).
Solid White Background
Glycine and Other Small Molecule Transmitters
🔸 Glycine: major inhibitory neurotransmitter in the spinal cord and brainstem. Acts on glycine receptors (Cl⁻ channels). Strychnine blocks glycine receptors → uninhibited motor neuron firing → convulsions. Glycine is also a co-agonist at the NMDA receptor (binding site distinct from the glutamate site).
🔸 Histamine: source is the tuberomammillary nucleus. H1 (Gq, wakefulness, allergy). H2 (Gs, gastric acid). H3 (Gi, presynaptic autoreceptor). First-generation antihistamines (diphenhydramine) cause sedation by blocking CNS H1.
🔸 Board pearl: Glycine is inhibitory at its own receptor (spinal cord) but excitatory as an NMDA co-agonist (brain). Context determines function.
Solid White Background
Neuropeptides and Endocannabinoids
🧷 Endogenous opioids: enkephalins, endorphins, dynorphins. Act on mu (μ, Gi, analgesia/euphoria/respiratory depression), kappa (κ, Gi, dysphoria/sedation), and delta (δ, Gi, analgesia) receptors. All are Gi-coupled → decreased cAMP, open K⁺ channels, close Ca²⁺ channels.
🧷 Substance P: nociceptive transmission in the dorsal horn. Released from C fibers.
🧷 Endocannabinoids (anandamide, 2-AG): retrograde messengers that inhibit presynaptic neurotransmitter release via CB1 receptors (Gi) in the CNS.
🧷 Board pearl: Mu receptor activation = analgesia + euphoria + respiratory depression + constipation + miosis. Naloxone/naltrexone are mu antagonists used for opioid reversal.
Solid White Background
Neurotransmitter Reuptake Transporters as Drug Targets
📍 SERT (serotonin transporter): blocked by SSRIs (fluoxetine, sertraline, etc.) and SNRIs.
📍 NET (norepinephrine transporter): blocked by SNRIs (venlafaxine, duloxetine), TCAs, and cocaine.
📍 DAT (dopamine transporter): blocked by cocaine, methylphenidate, and amphetamines (which also cause reverse transport/release).
📍 Board pearl: Cocaine blocks DAT, NET, and SERT — producing euphoria (dopamine), sympathetic activation (norepinephrine), and serotonergic effects. Amphetamines additionally cause active release of stored monoamines.
Solid White Background
MAO Inhibitors
🔹 MAO-A preferentially degrades serotonin, norepinephrine, and dopamine. MAO-B preferentially degrades dopamine.
🔹 Nonselective MAO inhibitors (phenelzine, tranylcypromine): block both isoforms, increasing all monoamines. Used for treatment-resistant depression.
🔹 Selective MAO-B inhibitors (selegiline, rasagiline): used as adjuncts in Parkinson disease to reduce dopamine breakdown.
🔹 Tyramine reaction: MAO normally degrades dietary tyramine in the gut. When MAO is inhibited, tyramine enters the circulation and causes massive NE release from sympathetic terminals → hypertensive crisis. Patients must avoid tyramine-rich foods (aged cheese, wine, cured meats).
🔹 Board pearl: MAOIs + tyramine-rich food = hypertensive crisis. MAOIs + serotonergic drugs (SSRIs, meperidine) = serotonin syndrome.
Solid White Background
COMT Inhibitors and Dopamine Pharmacology
⭐ COMT degrades catecholamines (including levodopa) in the periphery and CNS.
⭐ Entacapone and tolcapone inhibit COMT, extending levodopa’s half-life and bioavailability. Used as adjuncts to levodopa/carbidopa in Parkinson disease.
⭐ Carbidopa inhibits peripheral DOPA decarboxylase, preventing levodopa’s conversion to dopamine outside the CNS (reducing peripheral side effects like nausea and allowing more levodopa to reach the brain).
⭐ Board pearl: Levodopa + carbidopa is the most effective treatment for Parkinson disease. Carbidopa does NOT cross the BBB, so it only blocks peripheral conversion.
Solid White Background
Receptor Up- and Down-Regulation in Pharmacology
✅ Chronic agonist exposure → receptor downregulation and desensitization (tolerance). Chronic antagonist exposure → receptor upregulation and supersensitivity.
✅ Abrupt withdrawal of a chronic agonist unmasks a downregulated system → withdrawal symptoms (e.g., opioid withdrawal, benzodiazepine withdrawal).
✅ Abrupt withdrawal of a chronic antagonist unmasks an upregulated system → rebound effects (e.g., beta-blocker withdrawal → rebound tachycardia, clonidine withdrawal → rebound hypertension).
✅ Board pearl: Always taper drugs that cause receptor adaptation. Abrupt discontinuation can produce dangerous rebound effects.
Solid White Background
Dose-Response Relationships
🧠 Potency: the dose required to produce a given effect (reflected by EC50). A more potent drug requires a lower dose. Shifts the dose-response curve LEFT.
🧠 Efficacy: the maximum effect a drug can produce (the plateau of the dose-response curve). A more efficacious drug has a higher ceiling.
🧠 Competitive antagonists shift the curve RIGHT (overcome by increasing agonist concentration) without reducing maximum efficacy. Non-competitive antagonists reduce maximum efficacy regardless of agonist concentration.
🧠 Board pearl: Potency = position of curve (left vs right). Efficacy = height of plateau. Competitive antagonist = right shift. Non-competitive = reduced maximum.
Solid White Background
Therapeutic Index and Safety
⚡ Therapeutic index (TI) = TD50/ED50 (or LD50/ED50 in animal studies). A higher TI indicates a wider margin of safety.
⚡ Drugs with narrow TI require close monitoring: lithium, warfarin, digoxin, theophylline, aminoglycosides, phenytoin.
⚡ Board pearl: A drug with a narrow therapeutic index has a small difference between therapeutic and toxic doses, requiring careful dosing and monitoring.
Solid White Background
Clinical Pitfalls
📌 Confusing nicotinic and muscarinic effects of ACh: nicotinic = NMJ and ganglia (fast, ionotropic). Muscarinic = end-organ parasympathetic (slow, metabotropic).
📌 Forgetting that amphetamines cause monoamine RELEASE (not just reuptake blockade like cocaine).
📌 Missing the tyramine interaction with MAOIs: a dietary history is essential.
📌 Confusing MAO-A vs MAO-B selectivity: MAO-A = serotonin predominant. MAO-B = dopamine predominant. Nonselective MAOIs block both.
Solid White Background
Board Question Stem Patterns
📣 Drug that increases frequency of Cl⁻ channel opening at GABA-A → benzodiazepine.
📣 Drug that increases duration of Cl⁻ channel opening at GABA-A → barbiturate.
📣 Patient on MAOI who eats aged cheese and develops severe headache and hypertension → tyramine-induced hypertensive crisis.
📣 Patient on SSRI started on MAOI develops clonus, hyperthermia, agitation → serotonin syndrome.
📣 Drug that blocks peripheral DOPA decarboxylase without crossing the BBB → carbidopa.
📣 Elevated urinary 5-HIAA with flushing and diarrhea → carcinoid (serotonin-producing tumor).
📣 Seizures in a patient on isoniazid → pyridoxine depletion reducing GAD activity and GABA synthesis.
Solid White Background
One-Line Recap
🔸 Neurotransmitter pharmacology centers on the lifecycle of each transmitter (synthesis via rate-limiting enzymes like tyrosine hydroxylase and tryptophan hydroxylase, vesicular storage via VMAT, Ca²⁺-dependent release, receptor binding at ionotropic or metabotropic subtypes, and termination via reuptake transporters or degradation by AChE/MAO/COMT), with drugs targeting each step (SSRIs block SERT, cocaine blocks DAT/NET, benzodiazepines enhance GABA-A, MAOIs prevent monoamine breakdown) and clinical consequences determined by receptor adaptation (tolerance, dependence, withdrawal, and rebound) and dose-response principles (potency, efficacy, therapeutic index).
Solid White Background
bottom of page